ArticleInternational journal of clinical oncology2026
The surrogacy of disease-free survival for overall survival in locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionDisease-free survival (DFS) is increasingly proposed as a surrogate endpoint for overall survival (OS) in oncology trials, yet its validity in esophageal squamous cell carcinoma (ESCC) remains unconfirmed. This study evaluated the surrogacy of DFS for OS in patients with locally advanced ESCC receiving neoadjuvant therapy.
methodsIndividual patient data from a prospectively maintained cohort of patients who underwent neoadjuvant therapy followed by radical esophagectomy (N = 578) were analyzed. Individual-level surrogacy was assessed by comparing long-term OS with expected survival in a demographically matched general population using standardized mortality ratios (SMR) and landmark analysis. Trial-level surrogacy was evaluated via weighted linear regression of treatment effects on DFS and OS across published clinical trials.
resultsPatients remaining recurrence-free at 3 years achieved a 5-year OS rate of 93.0%, comparable to the matched general population (SMR = 0.935; 95% CI: 0.491-1.380). Conversely, early recurrence was associated with substantially worse outcomes, with a 51.3% absolute risk difference in 5-year OS between groups in landmark analysis. At the trial level, short-term DFS demonstrated a strong correlation with OS (R
conclusionsShort-term DFS is robustly correlated with long-term OS and may serve as a potential surrogate endpoint in locally advanced ESCC following neoadjuvant therapy, supported by both individual- and trial-level evidence. Patients achieving 3-year recurrence-free status exhibit long-term survival indistinguishable from the general population, reinforcing the clinical utility of DFS as an early efficacy marker in neoadjuvant trials.
Indexed as
Identifiers
42706459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.